Etira selected as a 2022 BioNTX rising starIlona Margolis, September 23, 2022
Dallas Texas, September 23, 2022. We are pleased to announce that Etira has been selected as a 2022 BioNTX rising star.
The BioNTX iC³ Life Science Summit is a two-day conference, held on September 22-23, 2022 that serves as a forum where industry leaders come together. Here we discuss strategy, exhibit the broad spectrum of bioscience research in North Texas, and where the latest innovation, products and services can be seen.
Every year BioNTX selects Rising Stars in the life science and healthcare innovation industry based on their success and the impact they have or will have improving patient outcomes and the environment. Each company had the opportunity to present their successes, achievements, and how they continue to impact healthcare and the ecosystem in North Texas. Rising Stars at the 2022 iC³ Life Science Summit included, Axcess Instruments, Colossal Biosciences, etiraRx, Evolve Biologics, Lantern Pharma Inc. (Nasdaq: LTRN), NemaLife, Inc., Perspectum Ltd, and VaxDome. Congratulations to all the winners
Link for the BioNTX website can be accessed here
EtiraRx is a privately owned Dallas-based biotech startup focused on developing the next generation of cancer therapies. EtiraRx is advancing their first small molecule drug, ERX-315, to phase I clinical trials later this year for patients with metastatic breast cancer.
- One year later, highest almetric score for any paper published in Nature Cancer!
- Positive preclinical data presented at AACR 2023
- Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
- Preclinical data on TNBC presented at SABCS 2022
- Etira founder Dr. Jung-Mo Ahn highlighted in local press